Momenta Pharma petition for rehearing denied by Court of Appeals Momenta Pharmaceuticals announced that the United States Court of Appeals for the Federal Circuit denied its request for a rehearing en banc to reconsider its three-judge panel opinion in the case of Momenta Pharmaceuticals vs. Amphastar Pharmaceuticals, Inc. The request for all active judges of the court to reconsider a panel decision, known as rehearing en banc, is only granted upon a majority vote. "We will continue to pursue our appellate options and we plan to file a petition for certiorari, asking the Supreme Court to review this case," said Craig Wheeler, president and CEO of Momenta.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: Adesto Technologies (IOTS) initiated with a Buy at Roth Capital... American Farmland (AFCO) initiated with an Outperform at Oppenheimer... Blackstone (BX) initiated with a Neutral at JPMorgan... California Resources (CRC) initiated with a Buy at Ladenburg... Calumet Specialty Products (CLMT) initiated with a Neutral at Goldman... Clearfield (CLFD) initiated with a Buy at Lake Street... Coherus Biosciences (CHRS) initiated with an Overweight at Barclays... Copa Holdings (CPA) initiated with a Buy at HSBC... GOL Linhas (GOL) initiated with a Reduce at HSBC... HP Enterprise (HPE) initiated with a Hold at Maxim... Himax (HIMX) initiated with an Overweight at Morgan Stanley... Horizon Pharma (HZNP) reinstated with a Buy at Jefferies... Match Group (MTCH) initiated with a Buy at Axiom... Mirati Therapeutics (MRTX) initiated with a Neutral at Citi... Momenta (MNTA) initiated with an Equal Weight at Barclays... MyoKardia (MYOK) initiated with an Outperform at Cowen... Revance (RVNC) initiated with a Buy at Guggenheim.